DoW Lung Cancer Translational Research Award

The DoW Lung Cancer Translational Research Award supports advanced translational research that will foster transformation of promising ideas in lung cancer into clinical applications. The funding mechanism intends to support a broad range of translational studies, including advanced/late-stage preclinical work or correlative studies, and pilot clinical trials of novel interventions. The award requires research to address at least one of the FY26 LCRP areas of emphasis. Some key points to consider include: • The award is open to any type of entity, subject to any clarification in the text field entitled "Additional Information on Eligibility". • The estimated funding for the award is $9,100,000, with 6 awards expected to be made. • The application submission period is from May 05, 2026, to Sep 02, 2026. • The award is a grant, and the funding activity category is Science and Technology and other Research and Development.